Kalfa Lab

Kalfa Lab

Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. American Journal of Human Genetics. 2020; 107:1149-1156.

Risinger, M; Kalfa, TA. Red cell membrane disorders: structure meets function. Blood. 2020; 136:1250-1261.

Konstantinidis, DG; Pushkaran, S; Johnson, JF; Cancelas, JA; Manganaris, S; Harris, CE; Williams, DA; Zheng, Y; Kalfa, TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012; 119:6118-6127.

Risinger, M; Kim, PS; Rodriguez, RX; Narvaez Rivas, M; Setchell, KD R; Zhang, W; Kalfa, TA. Hemolytic anemia and macrothrombocytopenia: a lipid problem?. American Journal of Hematology. 2023.

Yenwongfai, LN; Arora, R; Smith, AP; Kalfa, T; Husami, A; Radulescu, V; Myers, K; Lorsbach, R. Pediatric myelofibrosis due to compound heterozygous MPIG6B mutations in a patient of European ancestry. Pediatric Blood and Cancer. 2023; 70.

Hernández, G; Romero-Cortadellas, L; Ferrer-Cortès, X; Venturi, V; Dessy-Rodriguez, M; Olivella, M; Husami, A; de Soto, CP; Morales-Camacho, RM; Villegas, A; et al. Mutations in the RACGAP1 gene cause autosomal recessive congenital dyserythropoietic anemia type III. Haematologica. 2023; 108:581-587.

Noel, JG; Ramser, SW; Pitstick, L; Bonamer, JP; Mackenzie, B; Seu, KG; Kalfa, TA; Cancelas, JA; Gardner, JC. M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling. Scientific Reports. 2022; 12.

Voulgaridou, A; Elgammal, Y; Husami, A; Emberesh, S; Seu, K; Ramamoorthy, M; Trump, L; Barasa, N; Nelson, AS; Lorsbach, RB; et al. De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts. Blood. 2022; 140:1234-1235.

Seu, K; Voulgaridou, A; Stewart, M; Meznarich, J; Johnson, C; Junge, H; Mackenzie, B; Blanc, L; Cancelas, JA; Kalfa, TA. Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis. Blood. 2022; 140:8190-8191.

Romano, L; Seu, KG; Papoin, J; Muench, DE; Konstantinidis, D; Olsson, A; Schlum, K; Chetal, K; Chasis, JA; Mohandas, N; et al. Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis. Blood. 2022; 140:1621-1634.

Gibson, SJ; Kalfa, TA; DeStefano, CB. Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. American Journal of Hematology. 2022; 97:1384-1385.

Bello, A; Casanova, A; Arias, A; Kalfa, T; Kussick, S. MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia. 2022; 22 Suppl 2.

Bello, A; Casanova, A; Arias, A; Kalfa, T; Kussick, S. Poster: MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia. 2022; 22.

T., C; A., LA L; R., B; T., K; J., K; J., B; C., T; K., W; S., S. P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere. 2022; 6:43-44.

M., T; R., B; R., H; M., I; I., O; T., K; F., K; J., G; P., S; E., WU; et al. O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH. HemaSphere. 2022; 6:02-03.

Tu, Z; Fan, C; Davis, AK; Hu, M; Wang, C; Dandamudi, A; Seu, KG; Kalfa, TA; Lu, QR; Zheng, Y. Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling. Cell Reports. 2022; 40.

Noomuna, P; Hausman, JM; Sansoya, R; Kalfa, T; Risinger, M; Low, PS. Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. FASEB Journal. 2022; 36.

Forsyth, S; Schroeder, P; Geib, J; Vrishabhendra, L; Konstantinidis, DG; LaSalvia, K; Ribadeneira, MD; Wu, E; Kelly, P; Kalfa, TA. Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Clinical Pharmacology in Drug Development. 2022; 11:654-665.

Schroeder, P; Fulzele, K; Forsyth, S; Ribadeneira, MD; Guichard, S; Wilker, E; Marshall, CG; Drake, A; Fessler, R; Konstantinidis, DG; et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Journal of Pharmacology and Experimental Therapeutics. 2022; 380:210-219.

Tseng, SY; Gao, Z; Kalfa, TA; Ollberding, NJ; Tabbah, S; Keller, R; Cnota, JF. Altered erythropoiesis in newborns with congenital heart disease. Pediatric Research. 2022; 91:606-611.

Kalfa, TA. Diagnosis and clinical management of red cell membrane disorders. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2021; 2021:331-340.

Gutierrez, M; Shamoun, M; Seu, KG; Tanski, T; Kalfa, TA; Eniola-Adefeso, O. Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients. Scientific Reports. 2021; 11.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases. 2021; 90.

Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology. 2021; 194:617-625.

Newby, GA; Yen, JS; Woodard, KJ; Mayuranathan, T; Lazzarotto, CR; Li, Y; Sheppard-Tillman, H; Porter, SN; Yao, Y; Mayberry, K; et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021; 595:295-302.

Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68.

Sadaf, A; Seu, KG; Thaman, E; Fessler, R; Konstantinidis, DG; Bonar, HA; Korpik, J; Ware, RE; McGann, PT; Quinn, CT; et al. Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12.

Brindley, EC; Papoin, J; Kennedy, L; Robledo, RF; Ciciotte, SL; Kalfa, TA; Peters, LL; Blanc, L. Rasa3 regulates stage-specific cell cycle progression in murine erythropoiesis. Blood Cells, Molecules, and Diseases. 2021; 87.

Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al. Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells, Molecules, and Diseases. 2021; 87.

Kim, S; Khoriaty, R; Li, L; McClune, M; Kalfa, TA; Wu, J; Peltier, D; Fujiwara, H; Sun, Y; Oravecz-Wilson, K; et al. ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. Journal of Clinical Investigation. 2021; 131.

Voulgaridou, A; Kalfa, TA. Autoimmune Hemolytic Anemia in the Pediatric Setting. Journal of Clinical Medicine. 2021; 10.

Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. American Journal of Human Genetics. 2020; 107:1149-1156.

Remiker, A; Haslam, D; Kalfa, TA. A painless erythematous swelling of the external ear as a manifestation of Lyme disease: a case report. Journal of Medical Case Reports. 2020; 14.

Rai, P; Roy, S; Konstantinidis, DG; Ponny, SR; Mpollo, ME M; Shrestha, A; Kalfa, TA; Malik, P. Angiotensin Signaling Is Essential for Stress Erythropoiesis but Results in Retention of Dysfunctional Mitochondria in Erythrocytes That Generate Excessive Reactive Oxygen Species. Blood. 2020; 136:31-32.

Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT. Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood. 2020; 136:16-17.

Brown, RC; Cruz, K; Kalfa, TA; Kuypers, FA; Saraf, SL; Estepp, JH; Smart, LR; Malik, P; Lerman, M; Mayer, R; et al. FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. Blood. 2020; 136:19-20.

Rothman, JA; Stevens, JL; Gray, FL; Kalfa, TA. How I approach hereditary hemolytic anemia and splenectomy. Pediatric Blood and Cancer. 2020; 67.

Risinger, M; Kalfa, TA. Red cell membrane disorders: structure meets function. Blood. 2020; 136:1250-1261.

Noomuna, P; Risinger, M; Zhou, S; Seu, K; Man, Y; An, R; Sheik, DA; Wan, J; Little, JA; Gurkan, UA; et al. Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. British Journal of Haematology. 2020; 190:599-609.

Hall, BJ; Reiter, AJ; Englum, BR; Rice, HE; Rothman, JA; Davidoff, AM; Nottage, K; Oldham, KT; Scott, JP; Smithers, CJ; et al. Long‐term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer. 2020; 67.

Barnes, BJ; Vagrecha, A; LaPan, M; Kalfa, TA; Blanc, L. Novel role(s) for Irf5 in controlling myelopoiesis and erythropoiesis. Journal of Immunology. 2020; 204:63.1-63.1.

Niss, O; Lorsbach, RB; Buchbinder, DK; Chonat, S; McLemore, ML; McCavit, T; Schwartz, JH; Meznarich, J; Seu, K; Zhang, W; et al. Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR). Blood. 2019; 134:3521-3521.

McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology. 2019; 94:871-879.

Chonat, S; Risinger, M; Sakthivel, H; Niss, O; Rothman, JA; Hsieh, L; Chou, ST; Kwiatkowski, JL; Khandros, E; Gorman, MF; et al. The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Frontiers in Physiology. 2019; 10.

Risinger, M; Emberesh, M; Kalfa, TA. Rare Hereditary Hemolytic Anemias: Diagnostic Approach and Considerations in Management. Hematology/Oncology Clinics of North America. 2019; 33:373-392.

Risinger, M; Christakopoulos, GE; Schultz, CL; McGann, PT; Zhang, W; Kalfa, TA. Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity. Pediatric Blood and Cancer. 2019; 66.

Bianchi, P; Fermo, E; Glader, B; Kanno, H; Agarwal, A; Barcellini, W; Eber, S; Hoyer, JD; Kuter, DJ; Maia, TM; et al. Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology. 2019; 94:149-161.

Kalfa, TA. Acquired Hemolytic Anemias. Concise Guide to Hematology. 2019.